CD33 and acute myeloid leukemia: Adoptive Cell Therapy—Following favorable ongoing studies in lymphoid malignancies, chimeric antigen receptor-transduced T cells (CART), which are synthetic transmembrane constructs that combine the specificity of antibody target recognition with the potent effector mechanisms of T-cell immunity, have been designed to target CD33 (CART33) and CD123 (CART123) in AML.